A ninth case of thrombosis with thrombocytopenia (TIPIV) was identified in Quebec following the administration of the AstraZeneca vaccine on Tuesday.
The person has been taken care of and is recovering at his home, the Ministry of Health and Social Services (MSSS) noted in a press release. The evolution of his state of health would also be favorable.
This individual was receiving a first dose of a vaccine against COVID-19.
This is the ninth case of thrombosis in Quebec in connection with the AstraZeneca product. There is about one case per 50,000 doses administered during a first injection, but the risks of complications are much lower during the second inoculation, being one in 600,000, said the MSSS.
Thrombosis can develop within 4 to 20 days of vaccination. Its symptoms are shortness of breath, stomach and chest pain, swelling of the legs, a severe headache, blurred vision or bruising on the skin.